Does regional lymph node irradiation improve the outcome of N0 and pN0 breast cancer?
This study compares the outcome of 76 patients with N0 breast carcinoma, node-negative at axillary lymph node dissection (pN0) after neoadjuvant chemotherapy (NeoCT), treated with (RLNI+, 39 patients) or without (RLNI-, 37 patients) elective regional lymph node areas irradiation. For RLNI- and RLNI+ groups respectively at 10 years, survival without local-regional recurrence was 95% and 91% (p = .59), survival without distant metastasis was 97% and 78% (p = .018) and overall survival was 96% and 75% (p = .013). Clinical size < 4 cm was a strong pronostic factor.
Gilliot
Olivier
O
Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand F-63011, France.
Durando
Xavier
X
Abrial
Catherine
C
Bellière
Aurélie
A
Gimbergues
Pierre
P
Thivat
Emilie
E
Planchat
Eloïse
E
Lapeyre
Michel
M
Kwiatkowski
Fabrice
F
Toledano
Ivan
I
Chollet
Philippe
P
Nabholtz
Jean-Marc
JM
Verrelle
Pierre
P
D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000532:radiotherapy*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis